Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Aichi Cancer Center · Yonsei University · +15 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,130
total citations
- FWCI
- 70.12
- Percentile
- 100%
- References
- 29
Citations per year
Authors
18Topics & keywords
Topics
Keywords
- Pembrolizumab
- Medicine
- Internal medicine
- Adverse effect
- Cancer
- Clinical trial
- Response Evaluation Criteria in Solid Tumors
- Phases of clinical research
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.